Compare Eos Energy Enterprises Inc (EOSE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs TG Therapeutics Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.53 (market cap $1.01B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 8.1× Eos Energy Enterprises Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and TG Therapeutics Inc for 16 Days on average.
| EOSE | TGTX | |
|---|---|---|
Market Cap | $1.01B | $8.16B |
Volume | 39,626,541 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $19.19 | $59.06 |
52-Week Low | $2.77 | $26.94 |
Typical Hold Time | 16 Days | 16 Days |
Enterprise Value | $1.34B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.575, down 16.94% in the last session, reflecting ongoing volatility despite positive business developments. The company shows rapid revenue growth with $214M projected for 2026 but faces significant profitability challenges with a -246.76% net income margin. Recent catalysts include an $87M Department of Energy loan advance and a major partnership with Google for a $350M West Virginia energy project announced September 2, 2026.
While analyst consensus remains cautiously optimistic with a $7.10 price target representing 176% upside, the stock carries substantial risk due to persistent losses and high debt-to-asset ratio of 91.87%. The technical picture is bearish with weak momentum, though oversold RSI levels may indicate potential for near-term bounce. Investment appeal hinges on successful execution of production scaling and path to profitability.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
